FOXD1 was also recognized as a cancer‐promoter in various human malignancies, such as melanoma (Wu et al., 2018), lung cancer (Li et al., 2018), glioma (Cheng et al., 2016), colorectal cancer (Zhang et al., 2018), and breast cancer (Zhao et al., 2015). Here, FOXD1 is linked to glioma.